Security key
140755109
Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA)
CUSIP: 140755109
Q1 2020 13F Holders as of 31 Mar 2020
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 32,217,643
- Total 13F value
- $425,460,027
- Share change
- +918,444
- Put/Call ratio
- 57%
- SEC-reported price per share
- $13.21
- Number of holders
- 130
- Value change
- +$9,271,004
- Number of buys
- 50
- Number of sells
- 73
- Shares outstanding
- 54,790,889
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2020
Institutions
130
Top holders
10
CARA full security history
Ownership snapshot
Full 13F holder table
Tvardi Therapeutics, Inc. SEC filings
Tvardi Therapeutics, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of CARA - Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
PRICE T ROWE ASSOCIATES I...
Disclosed value leader
PRICE T ROWE ASSOCIATES I...
Comparable rows
15/15
Latest evidence
31 Dec 2019
13F
Lead comparable stake: 8.5%
Showing 1-6 of 15 holder rows.
Quick read
PRICE T ROWE ASSOCIATES INC /MD/ leads the comparable SEC ownership view at 8.5%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens PRICE T ROWE ASSOCIATES INC /MD/'s linked filing trail.
Comparable ownership
Top 5
PRICE T ROWE ASSOCIATES INC /MD/
8.5%
BlackRock Finance, Inc.
6.5%
RHO CAPITAL PARTNERS INC
5.8%
FARALLON CAPITAL MANAGEMENT, L.L.C.
4.2%
VANGUARD GROUP INC
4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
Company
|
8.5%
|
$75,082,000
4,660,614 shares
|
— | 31 Dec 2019 |
| BlackRock Finance, Inc. |
13F
Company
|
6.5%
|
$57,132,000
3,546,310 shares
|
— | 31 Dec 2019 |
| RHO CAPITAL PARTNERS INC |
13F
Company
|
5.8%
|
$51,440,000
3,193,057 shares
|
— | 31 Dec 2019 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. |
13F
Company
|
4.2%
|
$37,053,000
2,300,000 shares
|
— | 31 Dec 2019 |
| VANGUARD GROUP INC |
13F
Company
|
4%
|
$34,984,000
2,171,545 shares
|
— | 31 Dec 2019 |
| FIRST MANHATTAN CO. LLC. |
13F
Company
|
2.6%
|
$23,237,000
1,442,421 shares
|
— | 31 Dec 2019 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2020
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
130
Shares
32,217,643
Rows available
130
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2020 vs Q1 2020 Across Filers
Q1 2020 holders
130
Q1 2020 holders
130
Holder diff
0
| Investor | Q1 2020 Shares | Q1 2020 Shares | Share Diff | Share Chg % | Q1 2020 value | Q1 2020 value | Value change | Value Chg % |
|---|